热休克蛋白70和90表达水平与结直肠癌肝转移化疗疗效的关系

目的探讨热休克蛋白（HSP）70和HSP90的表达与结直肠癌肝转移化疗疗效的关系。方法分析52例手术切除了原发病灶而未能切除肝转移病灶并进行奥沙利铂、氟尿嘧啶及四氢叶酸钙化疗方案（FOLFOX4方案）化疗的结直肠癌肝转移患者的临床资料，通过cT检查比较化疗前后肝转移病灶数目及大小的变化：采用亲和免疫组织化学方法测定原发肿瘤组织HSP70和HSP90的表达：分析HSP70和HSP90的表达与化疗疗效间的关系。结果HSP70高表达者，部分缓解（PR）率为33．3％，低表达者PR率为64．5％，两者差异有统计学意义（P〈0．05）；HSP90高表达者，PR率为50％。低表达者PR率为53．1％，两者差异无统计学意义（P〉0．05）。结论对于HSP70低表达的结直肠癌肝转移患者．FOLFOX4方案化疗的疗效可能优于HSP70高表达者；HSP90的表达与其疗效无关。

Associntion between expressions of HISP70, HSP90 and efficacy of chemotherapy in colorectal cancer patients with unresectable liver metastasis

Objective To investigate the association between expressions of HSP70, HSP90 and efficacy of chemotherapy in eolorectal cancer patients with unresectable liver metastasis. Methods Data of 52 colorectal cancer cases, whose primary colorectal focuses were resected but hepatic metastatic tumors were unresectable, were reviewed retrospectively. All the patients underwent FOLFOX4 regimen well. Immunohistochemistry assay was applied to determine the expressions of HSP70 and HSP90 in primary focus tissues. The number and size of hepatic metastatic tumors pre- and post-chemotherapy were compared by CT scanning. Results Partial remission (PR) rate was 33.3% in cases with up-regulated expression of HSPT0, while 64.5% in eases with down-regulated expression of HSP70, whose difference was significant. PR rate was 50% in cases with up-regulated expression of HDP90, and 53.1% in the others with down-regulated expression of HSP90, whose difference was not siguificant. Conclusions FOLFOX4 regimen has advantages in cases with lower HSP70 expression over those with higher HSP70 expression. HSP90 expression level is not associated with the efficacy of FOLFOX4 regimen.